Raphael Pharmaceutical Net Income

The latest net income for RAPH is $-980K as of June 2026. That compares with $-1.5M in the prior-year period — up 33.4% year over year. That is below the sector sector average of $1.7T. Investors often review this figure alongside Raphael Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, RAPH's net income moved from $-1.5M to $-980K — a 33.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Raphael Pharmaceutical's operating scale or balance-sheet position.

Against its sector companies, RAPH currently prints $-980K for net income, while the sector average sits near $1.7T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Raphael Pharmaceutical's growth, margins, and balance sheet.

A net income figure of $-980K for RAPH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $1.7T. Explore the charts below for those layers of context.

After noting RAPH's net income ($-980K), review year-over-year change from $-1.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.